Search Result

Results for "

human subjects

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Amino Acid Derivatives (1) Antibiotic (2) Apical Sodium-Dependent Bile Acid Transporter (1) Biochemical Assay Reagents (1) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (2) GCGR (1) Interleukin Related (1) Isotope-Labeled Compounds (2) Opioid Receptor (2) Reference Standards (1)
By Research Areas:	Cancer (1) Infection (2) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (2)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0080

Aminohippurate sodium 4 Publications Verification Sodium p-aminohippurate; p-Aminohippuric acid sodium salt	Biochemical Assay Reagents
Aminohippurate sodium is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .

HY-112948

2-Methylbutyrylcarnitine	Endogenous Metabolite	Metabolic Disease
2-Methylbutyrylcarnitine is a fatty acid metabolite. 2-Methylbutyrylcarnitine is found mainly in the blood and urine of humans and animals and is produced through the pyruvate carboxylation pathway. 2-Methylbutyrylcarnitine exhibits high level in the plasma of subjects with steatohepatitis (NASH) and can be used as an indicator for the diagnosis of metabolic diseases .

HY-108229

6β-Naltrexol 6β-Hydroxynaltrexone	Drug Metabolite Opioid Receptor	Neurological Disease
6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-108229S

6β-Naltrexol-d3 6β-Hydroxynaltrexone-d₃	Isotope-Labeled Compounds Opioid Receptor Drug Metabolite	Neurological Disease
6β-Naltrexol-d₃ (6β-Hydroxynaltrexone-d₃) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Ritivixibat is an apical sodium-dependent bile acid transporter (ASBT/IBAT) inhibitor. Ritivixibat blocks ASBT/IBAT function, thereby reducing bile acid reabsorption, regulating bile acid homeostasis and alleviating liver injury. Ritivixibat protects cholangiocytes from damage caused by cytotoxic bile acids. Ritivixibat is applicable to research related to primary sclerosing cholangitis .

HY-N2086R

Ethyl palmitate (Standard) Ethyl hexadecanoate (Standard)	Reference Standards Others	Others
Ethyl palmitate (Standard) is the analytical standard of Ethyl palmitate. This product is intended for research and analytical applications. Ethyl palmitate, a fatty acid ethyl ester (FAEE), shows a marked preference for the synthesis of ethyl palmitate and ethyl oleate over other FAEEs in human subjects after ethanol consumption. Ethyl palmitate is used as a hair- and skin-conditioning agent .

HY-N2086S

Ethyl palmitate-d31 Ethyl hexadecanoate-d₃₁	Isotope-Labeled Compounds	Others
Ethyl palmitate-d₃₁ is the deuterium labeled Ethyl palmitate. Ethyl palmitate, a fatty acid ethyl ester (FAEE), shows a marked preference for the synthesis of ethyl palmitate and ethyl oleate over other FAEEs in human subjects after ethanol consumption. Ethyl palmitate is used as a hair- and skin-conditioning agent .

HY-171195

VU0631019	5-HT Receptor	Metabolic Disease
VU0631019 is a potent antagonist of 5-HT_2B, with the IC₅₀ of 29 nM. VU0631019 is predicted to have very limited potential for brain penetration in human subjects, as is predicted to be substrates for P-gp-mediated efflux in humans .

HY-171194

VU0530244	5-HT Receptor	Metabolic Disease
VU0530244 is a potent antagonist of 5-HT_2B, with the IC₅₀ of 17.3 nM. VU0530244 is predicted to have very limited potential for brain penetration in human subjects, as is predicted to be substrates for P-gp-mediated efflux in humans .

HY-123429

CK0683A	Antibiotic	Infection
CK0683A is a novel biaminourea antibiotic with antiplaque effects and demonstrated efficacy in experimental mouse dental disease models. A 12-week study in beagles compared its efficacy in terms of plaque and gingivitis reduction, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease is similar to that of humans. As a positive control for plaque and gingivitis reduction and staining, chlorhexidine acetate was selected because it is effective in both humans and dogs.

HY-123479

CK0492B	Antibiotic	Infection
CK0492B is a novel biaminourea antibiotic that has antiplaque properties in vitro and has shown efficacy in an experimental mouse dental disease model. A 12-week study in beagles compared its efficacy in reducing plaque and gingivitis, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease are similar to humans. Chlorhexidine acetate was selected as a positive control for plaque and gingivitis reduction and staining because it is effective in both humans and dogs.

HY-145545

1-Stearoyl-2-Adrenoyl-sn-glycero-3-PE PE(18:0/22:4); 1-Stearoyl-2-Docosatraenoyl-sn-glycero-3-PE	Endogenous Metabolite	Metabolic Disease
1-Stearoyl-2-adrenoyl-sn-glycero-3-PE is a phospholipid that contains stearic acid (HY-B2219) and adrenic acid (HY-W013215) at the sn-1 and sn-2 positions, respectively. 1-Stearoyl-2-adrenoyl-sn-glycero-3-PE levels are inversely correlated with subject age in mitochondria isolated from human post-mortem hippocampus.

HY-W611602

N-Methyl-L-histidine (hydrochloride) N-Me-His-OH (hydrochloride)	Amino Acid Derivatives	Others
N-Methyl-L-histidine (N-Me-His-OH) hydrochloride is a derivative of histidine, and a urinary metabolite with statistically significant differences in urinary secretion between male and female human .

HY-W209580

N-Nitrosobis(2-oxopropyl)amine	Drug Derivative	Cancer
N-Nitrosobis (2-oxopropyl) amine is a nitrosamine compound that has been the subject of significant research interest in the field of chemical carcinogenesis. N-nitrosobis (2-oxopropyl) amine (BOP) -treated Syrian golden hamsters are a chemical carcinogenesis model that represents human pancreatic cancer.

HY-P992150

Altrakincept	Interleukin Related	Inflammation/Immunology
Altrakincept is a recombinant hIL-4 receptor and IL-4 neutralizer. Altrakincept neutralizes endogenous IL-4, and prevents the decline of pulmonary function and acute asthma exacerbations after abrupt withdrawal of inhaled glucocorticoids .

HY-P992007

PF-06293620 RN909	GCGR	Metabolic Disease
PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .

Cat. No.	Product Name

HY-L928

GPCR Targeted Diversity Library	7,113 compounds
G protein-coupled receptors (GPCRs) are membrane proteins in humans and one of the most important targets in drug discovery. Approximately 35% of launched drugs are targeted GPCRs, making them a crucial class of targets in drug discovery. The orthosteric site of a GPCR is its endogenous ligand’s (such as neurotransmitters or hormones) binding site. This site plays a central role in signal transduction. Small molecules binding to this site typically contain a protonatable amino group, enabling the formation of salt bridges or hydrogen bonds with acidic residues in the binding pocket. In contrast, the allosteric site does not directly initiate signaling but modulates the signal intensity of the GPCR by altering or stabilizing the conformation of the orthosteric site. Small molecules binding to the allosteric site often contain multiple aromatic rings to occupy hydrophobic pockets and achieve their functional effects. MCE has collected over 7,113 reported bioactive molecules targeting GPCRs, covering Class A, B, and C GPCRs. These small molecules were subjected to AI representation to extract 2D and 3D features. Subsequently, we do screening by AI score based on similarity to identify molecules in diversity library highly similar to the reported bioactive molecules in both 2D and 3D, with a threshold greater than 0.7. Further screening based on cLogP was applied to select molecules with good lipophilicity, which facilitates the binding of small molecules to GPCRs. This diversity library can be widely applied to the discovery of compounds targeting GPCR proteins.

GPCR Targeted Diversity Library

7,113 compounds

G protein-coupled receptors (GPCRs) are membrane proteins in humans and one of the most important targets in drug discovery. Approximately 35% of launched drugs are targeted GPCRs, making them a crucial class of targets in drug discovery.

The orthosteric site of a GPCR is its endogenous ligand’s (such as neurotransmitters or hormones) binding site. This site plays a central role in signal transduction. Small molecules binding to this site typically contain a protonatable amino group, enabling the formation of salt bridges or hydrogen bonds with acidic residues in the binding pocket. In contrast, the allosteric site does not directly initiate signaling but modulates the signal intensity of the GPCR by altering or stabilizing the conformation of the orthosteric site. Small molecules binding to the allosteric site often contain multiple aromatic rings to occupy hydrophobic pockets and achieve their functional effects.

MCE has collected over 7,113 reported bioactive molecules targeting GPCRs, covering Class A, B, and C GPCRs. These small molecules were subjected to AI representation to extract 2D and 3D features. Subsequently, we do screening by AI score based on similarity to identify molecules in diversity library highly similar to the reported bioactive molecules in both 2D and 3D, with a threshold greater than 0.7. Further screening based on cLogP was applied to select molecules with good lipophilicity, which facilitates the binding of small molecules to GPCRs. This diversity library can be widely applied to the discovery of compounds targeting GPCR proteins.

Cat. No.	Product Name	Target	Research Area	Image